Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes 14 RNAi-Related Patent Applications

Premium
Title: Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
 
Number: 20070258952
 
Filed: May 4, 2007
 
Lead Inventor: Alex Tong, Baylor University (Murex Pharmaceuticals)
 
The invention “includes compositions and methods for the knockdown of one or more genes to a target cell in need of gene therapy by using an siRNA transgene that is integrated into a replication-competent, oncolytic adenovirus,” the patent application’s abstract states.
 

 
Title: Bladder Cancer-Related Nucleic Acids
 
Number: 20070259349
 
Filed: May 4, 2006
 
Lead Inventor: Isaac Bentwich, Rosetta Genomics
 
The patent application, its abstract states, claims “novel polynucleotides associated with bladder cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of bladder cancer. Also described … are methods that can be used to identify modulators of the disease-associated polynucleotides … [as well as] methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and microarray analysis.”
 

 
Title: Liver Cancer-Related Nucleic Acids
 
Number: 20070259350
 
Filed: May 4, 2006
 
Lead Inventor: Isaac Bentwich, Rosetta Genomics
 
The patent application, its abstract states, claims “novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of liver cancer. Also described … are methods that can be used to identify modulators of the disease-associated polynucleotides … [as well as] methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and microarray analysis.”
 

 
Title: Prostate Cancer-Related Nucleic Acids
 
Number: 20070259352
 
Filed: May 8, 2006
 
Lead Inventor: Isaac Bentwich, Rosetta Genomics
 
The patent application, its abstract states, claims “novel polynucleotides associated with prostate cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of prostate cancer. Also described … are methods that can be used to identify modulators of the disease-associated polynucleotides … [as well as] methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and microarray analysis.”
 

 
Title: Selecting and Stabilizing dsRNA Constructs
 
Number: 20070259785
 
Filed: Feb. 12, 2007
 
Lead Inventor: Gregory Heck, Monsanto
 
“The invention provides methods for selecting nucleotide sequences that yield dsRNA-mediated gene suppression in a target organism and enable their uptake by the target organism,” the patent application’s abstract states. “The invention further provides expression constructs that confer stabilized expression of such sequences in a transgenic host cell, and methods for their use. Also provided are organisms, cells, and tissues prepared by a method of the invention.”
 

 
Title: Compositions and Methods for Enhancing Discriminatory RNA Interference
 
Number: 20070259827
 
Filed: Jan. 25, 2007
 
Lead Inventor: Neil Aronin, University of Massachusetts
 
According to its abstract, the patent application claims “methods for enhancing discriminatory RNA silencing by RNA silencing agents. In particular, the invention provides methods for generating RNA silencing agents which can discriminate between target and non-target mRNAs that differ in sequence by only one nucleotide. Also provided are improved RNA silencing agents with enhanced discriminatory RNA silencing, e.g., single nucleotide discriminatory RNA silencing. The compositions and methods of the invention are useful in therapeutic strategies for treating genetic disorders associated with dominant, gain-of-function gene mutations.”
 

 
Title: siRNA Targeting EPH Receptor A4
 
Number: 20070260047
 
Filed: June 5, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to EPHA4.”
 

 
Title: siRNA Targeting Centromere Protein E, 312kDa
 
Number: 20070260048
 
Filed: May 29, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CENPE.”
 

 
Title: siRNA Targeting MAD2 Mitotic Arrest Deficient-Like
 
Number: 20070260049
 
Filed: June 5, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MAD2L2.”
 

 
Title: siRNA Targeting Minichromosome Maintenance Deficient 7
 
Number: 20070260050
 
Filed: June 7, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MCM7.”
 

 
Title: siRNA Targeting Pituitary Tumor-Transforming 1
 
Number: 20070260051
 
Filed: June 12, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PTTG1.”
 

 
Title: siRNA Targeting RAD1 Homolog
 
Number: 20070260052
 
Filed: June 12, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to RAD1.”
 

 
Title: Methods and Compositions for the Efficient Delivery of Therapeutic Agents to Cells and Animals
 
Number: 20070260055
 
Filed: Aug. 11, 2006
 
Inventor: Tariq Rana, University of Massachusetts
 
The invention, the patent application’s abstract states, “provides methods of carrying out the safe and reliable preparation of lipids comprising quaternary amines. Such lipids are especially suited for introducing therapeutic agents into cells or organisms. In particular, the lipids of the invention are suitable for the efficient transfer of gene therapy agents into mammalian cells or organisms in a cell type specific or tissue specific manner.”
 

 
Title: Methods and Sequences to Suppress Primate Huntington Gene Expression In Vivo
 
Number: 20070261126
 
Filed: Aug. 9, 2006
 
Lead Inventor: William Kaemmerer, Medtronic
 
The patent application, according to its abstract, claims “sequences, molecules, and methods used to suppress the expression of [Huntington’s diease] genes encoding for huntingtin protein in primates including Macaca mulatta and Homo sapiens. These sequences, molecules, and methods aid in the study of the pathogenesis of HD and can also provide a treatment for this disease by reducing HD mRNA without causing death, locomotor impairment, or cellular alterations of the Macaca mulatta and Homo sapiens.”

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.